Regenxbio (RGNX) Return on Capital Employed (2015 - 2025)
Regenxbio (RGNX) recorded quarterly Return on Capital Employed of 43.45% in Q4 2025, down 20.18% quarter-over-quarter from 36.15% in Q3 2025, and up 1648.0% on a YoY basis from 2.49% in Q4 2024.
Regenxbio (RGNX) Return on Capital Employed (2015 - 2025) Analysis & Trends
Regenxbio's Return on Capital Employed history runs 11 years deep, the most recent figure standing at 43.45% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 1648.0% year-over-year to 43.45%; the TTM figure through Dec 2025 stood at 43.45% (up 1648.0% YoY), while the FY2025 annual figure was 47.21%, up 877.0% from the prior year.
- Return on Capital Employed was 43.45% for Q4 2025 at Regenxbio, down from 36.15% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.35% in Q4 2021 to a low of 59.93% in Q4 2024.
- Historically, Return on Capital Employed has averaged 30.47% across 5 years, with a median of 38.75% in 2023.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed jumped 4277 bps in 2022, then plunged 6301 bps in 2023.
- A 5-year view of Return on Capital Employed shows it stood at 19.35% in 2021, then slumped by 287 bps to 36.1% in 2022, then slumped by 57 bps to 56.61% in 2023, then declined by 6 bps to 59.93% in 2024, then grew by 28 bps to 43.45% in 2025.
- The last three Return on Capital Employed figures came in at 43.45% (Q4 2025), 36.15% (Q3 2025), and 39.52% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Regenxbio | 315.11 Mn | 85.04 Mn | - | -43.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -43.45% |
| Sep 30, 2025 | -36.15% |
| Jun 30, 2025 | -39.52% |
| Mar 31, 2025 | -42.33% |
| Dec 31, 2024 | -59.93% |
| Sep 30, 2024 | -55.69% |
| Jun 30, 2024 | -49.65% |
| Mar 31, 2024 | -54.10% |
| Dec 31, 2023 | -56.61% |
| Sep 30, 2023 | -49.36% |
| Jun 30, 2023 | -44.89% |
| Mar 31, 2023 | -37.97% |
| Dec 31, 2022 | -36.10% |
| Sep 30, 2022 | 13.65% |
| Jun 30, 2022 | 13.97% |
| Mar 31, 2022 | 13.95% |
| Dec 31, 2021 | 19.35% |
| Sep 30, 2021 | -29.13% |
| Jun 30, 2021 | -17.74% |
| Mar 31, 2021 | -17.69% |